NEW YORK (GenomeWeb News) – Response Biomedical said this week that its board of directors has appointed Jeffrey Purvin to be CEO and a director, and that Peter Thompson has stepped down from the interim CEO position that he has held for nearly one year. Thompson will remain executive chairman of the company's board of directors.

Purvin has 30 years of experience marketing consumer and medical products, and he is a member of the board of directors, audit committee, and finance committee and chair of the compensation committee at Cardica.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.